Pharmaceutical - Pharmaceutical, Invega Sustenna

Filter

Popular Filters

Janssen files to expand label for Invega Sustenna to show delayed time to relapse in schizophrenia

Janssen files to expand label for Invega Sustenna to show delayed time to relapse in schizophrenia

15-07-2014

US health care giant Johnson & Johnson’s Europe-based subsidiary Janssen has submitted a supplemental…

Invega SustennaJanssenNeurologicalPharmaceuticalRegulationSchizophreniaUSA

Once-monthly Invega Sustenna reduces risk of relapse in schizoaffetive disorder

Once-monthly Invega Sustenna reduces risk of relapse in schizoaffetive disorder

07-05-2014

US health care giant Johnson & Johnson subsidiary Janssen Pharmaceuticals has released positive results…

Invega SustennaJanssenJohnson & JohnsonNeurologicalPharmaceuticalRegulationResearch

Janssen stops Ph III schizophrenia trial on good efficacy and relapse results

Janssen stops Ph III schizophrenia trial on good efficacy and relapse results

20-03-2014

Following an Independent Data Monitoring Committee recommendation based on positive efficacy, a Johnson…

Invega SustennaJanssenJohnson & JohnsonNeurologicalpaliperidone palmitatePharmaceuticalResearch

New Zealand proposal for paliperidone, risperidone and olanzapine depot injections funding

New Zealand proposal for paliperidone, risperidone and olanzapine depot injections funding

14-02-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to fund paliperidone…

Eli LillyHealthcareInvega SustennaJohnson & JohnsonNeurologicalNew ZealandPharmaceuticalPricingRisperdal ConstaZyprexa Relprevv

Janssen reveals new data on Xeplion in various stages of schizophrenia

Janssen reveals new data on Xeplion in various stages of schizophrenia

30-11-2013

US health care giant Johnson & Johnson’s (NYSE: JNJ) Europe-based subsidiary Janssen Pharmaceutica…

Invega SustennaJanssen PharmaceuticaJohnson & JohnsonNeurologicalPharmaceuticalResearchXeplion

Alkermes and J&J initiate Ph III trial of three-month Invega Sustenna

12-06-2012

USA-based Alkermes (Nasdaq: ALKS) and partner health care giant Johnson & Johnson (NYSE: JNJ) have started…

AlkermesInvega SustennaJohnson & JohnsonNeurologicalPharmaceuticalResearch

Back to top